Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biolat is a Latvian biotechnology company specializing in the extraction of biologically active substances from forest raw materials, particularly coniferous needles and bark. The company's core expertise lies in the development and production of Silbiol, a complex of biologically active substances with proven antibacterial, antiviral, and anti-inflammatory properties. Biolat utilizes these extracts to manufacture a variety of products, including dietary supplements, cosmetic ingredients, and environmentally friendly plant protection agents. Founded on research from the Latvian State Institute of Wood Chemistry, the company focuses on sustainable high-tech processing of forest biomass for health and agricultural applications. Their commercial portfolio includes products aimed at improving human health, animal welfare, and crop protection through natural, forest-derived solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biolat.